Evaluation of Phenoxybenzamine in the CFA Model of Pain Following Gene Expression Studies and Connectivity Mapping

Overview

Journal Mol Pain

Date 2010 Sep 18

PMID 20846436

Citations 32

Authors

Meiping Chang

Sarah Smith

Andrew Thorpe

Michael J Barratt

Farzana Karim

Affiliations

Soon will be listed here.

Abstract

Background: We have previously used the rat 4 day Complete Freund's Adjuvant (CFA) model to screen compounds with potential to reduce osteoarthritic pain. The aim of this study was to identify genes altered in this model of osteoarthritic pain and use this information to infer analgesic potential of compounds based on their own gene expression profiles using the Connectivity Map approach.

Results: Using microarrays, we identified differentially expressed genes in L4 and L5 dorsal root ganglia (DRG) from rats that had received intraplantar CFA for 4 days compared to matched, untreated control animals. Analysis of these data indicated that the two groups were distinguishable by differences in genes important in immune responses, nerve growth and regeneration. This list of differentially expressed genes defined a "CFA signature". We used the Connectivity Map approach to identify pharmacologic agents in the Broad Institute Build02 database that had gene expression signatures that were inversely related ('negatively connected') with our CFA signature. To test the predictive nature of the Connectivity Map methodology, we tested phenoxybenzamine (an alpha adrenergic receptor antagonist) - one of the most negatively connected compounds identified in this database - for analgesic activity in the CFA model. Our results indicate that at 10 mg/kg, phenoxybenzamine demonstrated analgesia comparable to that of Naproxen in this model.

Conclusion: Evaluation of phenoxybenzamine-induced analgesia in the current study lends support to the utility of the Connectivity Map approach for identifying compounds with analgesic properties in the CFA model.

Citing Articles

Novel tumor gene expression signatures improve the overall survival prediction efficiency over tumor mutation burden and PD-L1 expression in bladder carcinoma with checkpoint blockade immunotherapy.

Guo Y, Dai Y, Yin J, Song Y, Wang T, Zhang L Am J Cancer Res. 2024; 14(9):4411-4428.

PMID: 39417183 PMC: 11477819. DOI: 10.62347/TIMD7591.

Systematic computational strategies for identifying protein targets and lead discovery.

Kataria A, Srivastava A, Singh D, Haque S, Han I, Yadav D RSC Med Chem. 2024; 15(7):2254-2269.

PMID: 39026640 PMC: 11253860. DOI: 10.1039/d4md00223g.

A programmable protease-based protein secretion platform for therapeutic applications.

Wang X, Kang L, Kong D, Wu X, Zhou Y, Yu G Nat Chem Biol. 2023; 20(4):432-442.

PMID: 37872400 DOI: 10.1038/s41589-023-01433-z.

Network neighborhood operates as a drug repositioning method for cancer treatment.

Cuvitoglu A, Isik Z PeerJ. 2023; 11:e15624.

PMID: 37456868 PMC: 10340098. DOI: 10.7717/peerj.15624.

Satellite glial cells drive the transition from acute to chronic pain in a rat model of hyperalgesic priming.

Du J, Yi M, Xi D, Wang S, Liu B, Shao X Front Mol Neurosci. 2023; 16:1089162.

PMID: 36818653 PMC: 9931746. DOI: 10.3389/fnmol.2023.1089162.

References

Ahn K, Johnson D, Mileni M, Beidler D, Long J, McKinney M . Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol. 2009; 16(4):411-20. PMC: 2692831. DOI: 10.1016/j.chembiol.2009.02.013. View

Maccarrone M, Battista N, Centonze D . The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Prog Neurobiol. 2007; 81(5-6):349-79. DOI: 10.1016/j.pneurobio.2006.11.006. View

Verdi J, Ahmadiani A . Finasteride, a 5alpha-reductase inhibitor, potentiates antinociceptive effects of morphine, prevents the development of morphine tolerance and attenuates abstinence behavior in the rat. Horm Behav. 2007; 51(5):605-10. DOI: 10.1016/j.yhbeh.2007.02.008. View

HENDERSHOT L, FORSAITH J . Antagonism of the frequency of phenylquinone-induced writhing in the mouse by weak analgesics and nonanalgesics. J Pharmacol Exp Ther. 1959; 125(3):237-40. View

Fendrick A, Greenberg B . A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis. Osteopath Med Prim Care. 2009; 3:1. PMC: 2646740. DOI: 10.1186/1750-4732-3-1. View

Inchiosa Jr M, Kizelshteyn G . Treatment of complex regional pain syndrome type I with oral phenoxybenzamine: rationale and case reports. Pain Pract. 2008; 8(2):125-32. DOI: 10.1111/j.1533-2500.2007.00170.x. View

Lamb J, Ramaswamy S, Ford H, Contreras B, Martinez R, Kittrell F . A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003; 114(3):323-34. DOI: 10.1016/s0092-8674(03)00570-1. View

Crotty S, Johnston R, Schoenberger S . Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol. 2010; 11(2):114-20. PMC: 2864556. DOI: 10.1038/ni.1837. View

Kim T, Jiang S, Seng S, Cha K, Avraham H, Avraham S . The BTB domain of the nuclear matrix protein NRP/B is required for neurite outgrowth. J Cell Sci. 2005; 118(Pt 23):5537-48. DOI: 10.1242/jcs.02643. View

10.

Watanabe T, Masuyama J, Sohma Y, Inazawa H, Horie K, Kojima K . CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol. 2006; 120(3):247-59. DOI: 10.1016/j.clim.2006.05.006. View

11.

Rocca B, Spain L, Pure E, Langenbach R, Patrono C, FitzGerald G . Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest. 1999; 103(10):1469-77. PMC: 408457. DOI: 10.1172/JCI6400. View

12.

Monteleone G, Pallone F, Macdonald T . Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev. 2009; 20(2):185-91. DOI: 10.1016/j.cytogfr.2009.02.002. View

13.

Wu C, Qiu R, Wang J, Zhang H, Murai K, Lu Q . ZHX2 Interacts with Ephrin-B and regulates neural progenitor maintenance in the developing cerebral cortex. J Neurosci. 2009; 29(23):7404-12. PMC: 2759685. DOI: 10.1523/JNEUROSCI.5841-08.2009. View

14.

Maina F, Hilton M, Ponzetto C, Davies A, Klein R . Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons. Genes Dev. 1998; 11(24):3341-50. PMC: 316818. DOI: 10.1101/gad.11.24.3341. View

15.

Mitchell J, Maguire J, Davenport A . Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. Br J Pharmacol. 2009; 158(1):87-103. PMC: 2795236. DOI: 10.1111/j.1476-5381.2009.00252.x. View

16.

Yang H, Mitchell K, Keller J, Iadarola M . Peripheral inflammation increases Scya2 expression in sensory ganglia and cytokine and endothelial related gene expression in inflamed tissue. J Neurochem. 2007; 103(4):1628-43. DOI: 10.1111/j.1471-4159.2007.04874.x. View

17.

Maresz K, Pryce G, Ponomarev E, Marsicano G, Croxford J, Shriver L . Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med. 2007; 13(4):492-7. DOI: 10.1038/nm1561. View

18.

Ghostine S, Comair Y, Turner D, Kassell N, Azar C . Phenoxybenzamine in the treatment of causalgia. Report of 40 cases. J Neurosurg. 1984; 60(6):1263-8. DOI: 10.3171/jns.1984.60.6.1263. View

19.

Thacker M, Clark A, Marchand F, McMahon S . Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg. 2007; 105(3):838-47. DOI: 10.1213/01.ane.0000275190.42912.37. View

20.

Varoli L, Andreani A, Burnelli S, Granaiola M, Leoni A, Locatelli A . Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Bioorg Med Chem Lett. 2008; 18(9):2972-6. DOI: 10.1016/j.bmcl.2008.03.061. View